<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mpath ids='MPATH_73'>Growth arrest</z:mpath>-specific gene (Gas) 6 is a Î³-carboxyglutamic acid domain-containing protein, which shares 43% amino acid identity with protein S </plain></SENT>
<SENT sid="1" pm="."><plain>Gas6 has been shown to enhance <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell proliferation in vitro </plain></SENT>
<SENT sid="2" pm="."><plain>On the other hand, recent studies have demonstrated that Gas6 inhibits toll-like receptor-mediated immune reactions </plain></SENT>
<SENT sid="3" pm="."><plain>Immune reactions are known to affect intestinal <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>In this study, we investigated how Gas6 contributes to <z:mp ids='MP_0002006'>tumorigenesis</z:mp> in the intestine </plain></SENT>
<SENT sid="5" pm="."><plain>Administration of recombinant Gas6 weakly, but significantly, enhanced proliferation of <z:e sem="disease" ids="C0346627" disease_type="Neoplastic Process" abbrv="">intestinal cancer</z:e> cells (SW480 and HT29), whereas it suppressed the <z:mp ids='MP_0001845'>inflammatory responses</z:mp> of <z:chebi fb="0" ids="16412">Lipopolysaccharide</z:chebi> (LPS)-stimulated monocytes (<z:chebi fb="0" ids="46941">THP</z:chebi>-1) </plain></SENT>
<SENT sid="6" pm="."><plain>Compared with Gas6(+/+) mice, Gas6(-/-) mice exhibited enhanced azoxymethane/<z:chebi fb="0" ids="34674">dextran sulfate</z:chebi> <z:chebi fb="199" ids="26708">sodium</z:chebi> (DSS)-induced <z:mp ids='MP_0002006'>tumorigenesis</z:mp> and had a shorter survival </plain></SENT>
<SENT sid="7" pm="."><plain>Gas6(-/-) mice also exhibited more severe DSS-induced <z:hpo ids='HP_0002583'>colitis</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>DSS-treated Gas6(-/-) mice showed attenuated Socs1/3 messenger <z:chebi fb="40" ids="33697">RNA</z:chebi> expression and enhanced nuclear factor-kappaB activation in the colonic stroma, suggesting that the target of Gas6 is stromal cells </plain></SENT>
<SENT sid="9" pm="."><plain>Bone marrow transplantation experiments indicated that both epithelial cells and bone marrow-derived cells are Gas6 sources </plain></SENT>
<SENT sid="10" pm="."><plain>Furthermore, the number of <z:e sem="disease" ids="C0021841" disease_type="Neoplastic Process" abbrv="">intestinal tumors</z:e> in Apc(Min) Gas6(-/-) mice was higher than that in Apc(Min) Gas6(+/+) mice, resulting in shorter survival </plain></SENT>
<SENT sid="11" pm="."><plain>In a group of 62 patients with advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, Gas6 immunoreactivity in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> tissues was positively correlated with prognosis </plain></SENT>
<SENT sid="12" pm="."><plain>Thus, we revealed a unique in vivo inhibitory role of Gas6 during the progression of <z:e sem="disease" ids="C0021841" disease_type="Neoplastic Process" abbrv="">intestinal tumors</z:e> associated with suppression of stromal immune reactions </plain></SENT>
<SENT sid="13" pm="."><plain>These results suggest a novel therapeutic approach for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients by regulation of stromal immune responses </plain></SENT>
</text></document>